ARS Pharmaceuticals, Inc. (SPRY), on Thursday announced that the FDA has approved neffy 1 mg (epinephrine nasal spray) for the treatment of Type I allergic reactions, including anaphylaxis, in pediatric patients aged 4 years and older who weigh 15 to less than 30 kilograms.
This approval marks the first needle-free epinephrine treatment for this age group in over 35 years, addressing an unmet need for children and caregivers who fear using traditional needle-based auto-injectors.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com